[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601121":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":11,"id":49,"slug":11,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":11,"overallStatus":67,"whyStopped":11,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Keymed Biosciences Co.Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Stapokibatrt group","EXPERIMENTAL",null,[13],"Biological: Stapokibatrt",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BIOLOGICAL","Stapokibatrt","Stapokibatrt Subcutaneous injection",[9],[21],{"name":22,"affiliation":23,"role":24},"Lin Ma","Beijing Children's Hospital","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Qian Jia","CONTACT","028-88610620","qianjia@keymedbio.com",[32],{"facility":33,"status":11,"city":34,"state":35,"zip":11,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Beijing Children's Hospital Capital Medical University","Beijing","Beijing Municipality","China","CN",{"type":39,"coordinates":40},"Point",[41,42],116.39723,39.9075,{"lat":42,"lon":41},[45],{"name":22,"role":28,"phone":46,"phoneExt":11,"email":11},"+86 13601305676",{"type":48,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100601121",false,"NCT07106372","A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis","A Multi-center, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Stapokibatrt in Children With Atopic Dermatitis","Inclusion Criteria:\n\n* Voluntarily participate in the continuing study and sign the written Informed Consent Form(ICF).\n* Subjects who must complete the evaluation of Week 18 of the main study.\n* Have the ability to communicate well with the researcher and comply with the follow-up visits of the protocol.\n\nExclusion Criteria:\n\n* Planned major surgical procedure during the patient's participation in this study.\n* Any other circumstances in which the researcher deems not suitable to participate in this study.","ALL","2 Years","12 Years",{"count":59,"type":60},240,"ESTIMATED","INTERVENTIONAL",[63],"PHASE3","This is a multi-center, single-arm, open-label phase 3 study to evaluate the safety, efficacy, Pharmacokinetics(PK) and immunogenicity of Stapokibatrt in children with Atopic Dermatitis.",[66],"Atopic Dermatitis","NOT_YET_RECRUITING","2025-08-05",{"date":70,"type":71},"2025-08-06","ACTUAL",{"date":73,"type":60},"2025-09",{"date":75,"type":60},"2027-06",{"name":5,"class":6},1]